Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

196 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations.
Ciuffreda L, Del Bufalo D, Desideri M, Di Sanza C, Stoppacciaro A, Ricciardi MR, Chiaretti S, Tavolaro S, Benassi B, Bellacosa A, Foà R, Tafuri A, Cognetti F, Anichini A, Zupi G, Milella M. Ciuffreda L, et al. Among authors: anichini a. Neoplasia. 2009 Aug;11(8):720-31. doi: 10.1593/neo.09398. Neoplasia. 2009. PMID: 19649202 Free PMC article.
The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms.
Ciuffreda L, Di Sanza C, Cesta Incani U, Eramo A, Desideri M, Biagioni F, Passeri D, Falcone I, Sette G, Bergamo P, Anichini A, Sabapathy K, McCubrey JA, Ricciardi MR, Tafuri A, Blandino G, Orlandi A, De Maria R, Cognetti F, Del Bufalo D, Milella M. Ciuffreda L, et al. Among authors: anichini a. J Mol Med (Berl). 2012 Jun;90(6):667-79. doi: 10.1007/s00109-011-0844-1. Epub 2012 Jan 4. J Mol Med (Berl). 2012. PMID: 22215152
Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathways.
Tassi E, Zanon M, Vegetti C, Molla A, Bersani I, Perotti V, Pennati M, Zaffaroni N, Milella M, Ferrone S, Carlo-Stella C, Gianni AM, Mortarini R, Anichini A. Tassi E, et al. Among authors: anichini a. Clin Cancer Res. 2012 Jun 15;18(12):3316-27. doi: 10.1158/1078-0432.CCR-11-2232. Epub 2012 May 2. Clin Cancer Res. 2012. PMID: 22553342 Free PMC article.
Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells.
Loria R, Bon G, Perotti V, Gallo E, Bersani I, Baldassari P, Porru M, Leonetti C, Di Carlo S, Visca P, Brizzi MF, Anichini A, Mortarini R, Falcioni R. Loria R, et al. Among authors: anichini a. Oncotarget. 2015 Feb 20;6(5):2779-93. doi: 10.18632/oncotarget.2995. Oncotarget. 2015. PMID: 25576923 Free PMC article.
Semaphorin 5A drives melanoma progression: role of Bcl-2, miR-204 and c-Myb.
D'Aguanno S, Valentini E, Tupone MG, Desideri M, Di Martile M, Spagnuolo M, Buglioni S, Ercolani C, Falcone I, De Dominici M, Milella M, Rizzo MG, Calabretta B, Cota C, Anichini A, Trisciuoglio D, Del Bufalo D. D'Aguanno S, et al. Among authors: anichini a. J Exp Clin Cancer Res. 2018 Nov 19;37(1):278. doi: 10.1186/s13046-018-0933-x. J Exp Clin Cancer Res. 2018. PMID: 30454024 Free PMC article.
BRAF alterations are associated with complex mutational profiles in malignant melanoma.
Daniotti M, Oggionni M, Ranzani T, Vallacchi V, Campi V, Di Stasi D, Torre GD, Perrone F, Luoni C, Suardi S, Frattini M, Pilotti S, Anichini A, Tragni G, Parmiani G, Pierotti MA, Rodolfo M. Daniotti M, et al. Among authors: anichini a. Oncogene. 2004 Aug 5;23(35):5968-77. doi: 10.1038/sj.onc.1207780. Oncogene. 2004. PMID: 15195137
NFATc2 is a potential therapeutic target in human melanoma.
Perotti V, Baldassari P, Bersani I, Molla A, Vegetti C, Tassi E, Dal Col J, Dolcetti R, Anichini A, Mortarini R. Perotti V, et al. Among authors: anichini a. J Invest Dermatol. 2012 Nov;132(11):2652-60. doi: 10.1038/jid.2012.179. Epub 2012 Jun 21. J Invest Dermatol. 2012. PMID: 22718120 Free article.
196 results